| Here's Why Qiagen (QGEN) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-16 14:56:30 |
Czytaj oryginał (ang.) |
| Here's Why Qiagen (QGEN) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-15 14:46:21 |
Czytaj oryginał (ang.) |
| Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential |
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panels and QuantiFERON TB tests drive double-digit growth. Plus, QGEN seems to have a good competitive position across several niches. Also, QGEN's recent acquisition of Genoox and its AI-powered Franklin software expands their clinical bioinformatics capabilities for scalable genomic interpretation. |
seekingalpha.com |
2025-05-15 11:30:00 |
Czytaj oryginał (ang.) |
| QIAGEN Stock Gains Following the Acquisition of Genoox |
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio. |
zacks.com |
2025-05-13 12:10:46 |
Czytaj oryginał (ang.) |
| Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript |
Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Tycho Peterson - Jefferies Michael Ryskin - Bank of America Jan Koch - Deutsche Bank Jack Meehan - Nephron Research Dan Brennan - TD Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-08 18:48:10 |
Czytaj oryginał (ang.) |
| QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up |
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025. |
zacks.com |
2025-05-08 11:55:55 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings |
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-08 00:30:34 |
Czytaj oryginał (ang.) |
| Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates |
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago. |
zacks.com |
2025-05-07 23:20:43 |
Czytaj oryginał (ang.) |
| QIAGEN announces plans for transition in leadership of Supervisory Board |
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Meeting on June 26, 2025. The change comes after Mr. Rosen has decided to step down as Chairman of the Supervisory Board and as a Supervisory Board member upon completion of the Annual General Meeting. Mr. Rosen has served on. |
businesswire.com |
2025-05-07 20:20:00 |
Czytaj oryginał (ang.) |
| QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting |
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Boar. |
businesswire.com |
2025-05-07 12:45:00 |
Czytaj oryginał (ang.) |
| Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics |
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-05-06 14:20:53 |
Czytaj oryginał (ang.) |
| Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value |
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way. |
cnbc.com |
2025-05-03 14:47:42 |
Czytaj oryginał (ang.) |
| QGEN or RGEN: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-05-02 16:41:06 |
Czytaj oryginał (ang.) |
| Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth |
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:07 |
Czytaj oryginał (ang.) |
| QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control |
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy. This expanded offering supports standardized, high-precision quality contr. |
businesswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| Why Qiagen (QGEN) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-29 14:40:15 |
Czytaj oryginał (ang.) |
| QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 |
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These new developments will be showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30 in Chicago. Important updates include a new set of QIAseq panels for comprehensive genomic profiling (CGP) and a new QIAcuity digital PCR (dPCR). |
businesswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-16 14:50:52 |
Czytaj oryginał (ang.) |
| QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation |
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation. These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide and address different customer segments: QIAsymphony Connect, which marks the next generation of the flagship QIAsym. |
businesswire.com |
2025-04-15 05:30:00 |
Czytaj oryginał (ang.) |
| QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast |
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect. |
businesswire.com |
2025-04-08 15:22:00 |
Czytaj oryginał (ang.) |
| Qiagen N.V.: Some Clarity Needed Before Buying The Dip |
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. |
seekingalpha.com |
2025-02-25 18:39:39 |
Czytaj oryginał (ang.) |
| 2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62% |
Stock splits can be undertaken for several reasons. They can bring a stock's price down to make it more affordable for a wider range of investors. |
fool.com |
2025-02-23 09:00:00 |
Czytaj oryginał (ang.) |
| FFPE Tissue Samples for Genomics Study & Analysis Market to Cross US$ 1.5 Bn by 2034 with a Robust CAGR of 5.1%, Led by Key Players BioChain Institute, Amsbio, Cureline, Discovery Life Sciences, and QIAGEN - TMR |
The FFPE tissue samples for genomics study & analysis market is poised for significant growth, driven by rising cancer incidence, advancements in genomic technologies, and an increasing focus on personalized medicine. These samples play a crucial role in cancer research, enabling detailed genetic profiling and better therapeutic strategies. Despite challenges like regulatory constraints and high costs, emerging markets and innovations in sample preservation present promising growth opportunities for industry players. The FFPE tissue samples for genomics study & analysis market is poised for significant growth, driven by rising cancer incidence, advancements in genomic technologies, and an increasing focus on personalized medicine. These samples play a crucial role in cancer research, enabling detailed genetic profiling and better therapeutic strategies. Despite challenges like regulatory constraints and high costs, emerging markets and innovations in sample preservation present promising growth opportunities for industry players. |
globenewswire.com |
2025-02-18 13:13:00 |
Czytaj oryginał (ang.) |
| Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. |
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-02-13 12:05:00 |
Czytaj oryginał (ang.) |
| QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand |
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024. |
zacks.com |
2025-02-07 09:51:11 |
Czytaj oryginał (ang.) |
| Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript |
Qiagen N.V. (NYSE:QGEN ) Q4 2024 Earnings Conference Call February 6, 2025 10:00 AM ET Company Participants John Gilardi – Vice President, Head of Corporate Communications and Investor Relations Thierry Bernard – Chief Executive Officer Roland Sackers – Chief Financial Officer Conference Call Participants Tycho Peterson – Jefferies Michael Ryskin – Bank of America Securities Patrick Donnelly – Citi Doug Schenkel – Wolfe Research Dan Arias – Stifel Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Casey Woodring – J.P. |
seekingalpha.com |
2025-02-06 18:49:10 |
Czytaj oryginał (ang.) |
| Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-05 21:01:21 |
Czytaj oryginał (ang.) |
| Qiagen (QGEN) Q4 Earnings Lag Estimates |
Qiagen (QGEN) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.57 per share a year ago. |
zacks.com |
2025-02-05 20:46:09 |
Czytaj oryginał (ang.) |
| QIAGEN delivers solid Q4 2024 growth ahead of outlook |
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% to $521 million compared to Q4 2023, while sales at constant exchange rates (CER) of $525 million rose 3% and were above the outlook for at least $520 million CER and core sales (excluding discontinued products such as NeuMoDx and Dialunox) rose 4% CER. The adjusted operating income margin. |
businesswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent |
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the German Federal Patent Court (Bundespatentgericht) has ruled in its favor in a patent dispute against SD Biosensor, reaffirming the validity of an important patent protecting key innovations in its QuantiFERON technology. This ruling underscores the strength of QIAGEN's QuantiFERON intellectual property portfolio and protects the scientific advancements that have made QuantiF. |
businesswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now? |
QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties. |
zacks.com |
2025-01-30 10:31:08 |
Czytaj oryginał (ang.) |
| Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth |
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-29 13:06:10 |
Czytaj oryginał (ang.) |
| Strategic Collaborations Aid QGEN Stock Amid Competition |
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms. |
zacks.com |
2025-01-17 13:41:07 |
Czytaj oryginał (ang.) |
| QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million |
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repur. |
businesswire.com |
2025-01-16 18:05:00 |
Czytaj oryginał (ang.) |
| GMAB vs. QGEN: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-16 14:41:12 |
Czytaj oryginał (ang.) |
| QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase |
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return up to approximately $300 million (maximum EUR 281 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. This new repurchase comes after QIAGEN returned approximately $300 million to shareholders in early 2024 through a synthetic share repurchase. Together, these two programs represent $600 m. |
businesswire.com |
2025-01-12 15:05:00 |
Czytaj oryginał (ang.) |
| QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples |
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample. The new capabilities overcome the assay design challenges of currently available quantitative multiplex PCR methods, making QIAcuity digital PCR ideal for applications such. |
businesswire.com |
2025-01-10 03:30:00 |
Czytaj oryginał (ang.) |
| QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care |
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by the U.S. Food and Drug Administration (FDA) marks the second mini syndromic panel in the U.S. and made available for use with QIAstat-Dx systems, supporting QIAGEN's strategy to improve patient treatment options in this important market. |
businesswire.com |
2025-01-09 18:05:00 |
Czytaj oryginał (ang.) |
| Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report? |
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-09 15:15:32 |
Czytaj oryginał (ang.) |
| QGEN Stock Might Rise Following Partnership With Genomics England |
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content. |
zacks.com |
2025-01-08 09:56:11 |
Czytaj oryginał (ang.) |
| New Product Offerings Support QIAGEN's Shares Amid Currency Woes |
To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms. |
zacks.com |
2024-12-30 13:51:10 |
Czytaj oryginał (ang.) |
| Here's Why Qiagen (QGEN) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-30 12:51:26 |
Czytaj oryginał (ang.) |
| Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-13 12:56:26 |
Czytaj oryginał (ang.) |
| QIAGEN Stock Gains Following the Latest Launch of IPA Interpret |
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology. |
zacks.com |
2024-12-13 11:06:07 |
Czytaj oryginał (ang.) |
| QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data |
REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process o. |
businesswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements |
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments. |
zacks.com |
2024-12-09 11:15:34 |
Czytaj oryginał (ang.) |
| QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation |
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line. Launched in 2021, the updated EZ2 Connect has quickly become a market-leading instrument for sample preparation and data management, contributing to a total of more than 5,500 EZ series instruments placed globally. EZ2 Connect. |
businesswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Should You Continue to Retain QIAGEN Stock in Your Portfolio Now? |
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors. |
zacks.com |
2024-12-05 10:50:45 |
Czytaj oryginał (ang.) |
| Here's Why Qiagen (QGEN) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-29 12:40:24 |
Czytaj oryginał (ang.) |
| QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site |
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing. |
zacks.com |
2024-11-29 10:41:23 |
Czytaj oryginał (ang.) |
| QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools |
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels. |
zacks.com |
2024-11-28 10:45:17 |
Czytaj oryginał (ang.) |
| QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing |
BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of. |
businesswire.com |
2024-11-28 08:00:00 |
Czytaj oryginał (ang.) |
| QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis |
QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels |
globenewswire.com |
2024-11-27 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Qiagen (QGEN) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-25 12:56:36 |
Czytaj oryginał (ang.) |
| Innovations Support QIAGEN Shares Despite Macroeconomic Concerns |
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms. |
zacks.com |
2024-11-22 12:21:07 |
Czytaj oryginał (ang.) |
| Reasons to Retain QIAGEN Stock in Your Portfolio for Now |
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning. |
zacks.com |
2024-11-22 08:50:17 |
Czytaj oryginał (ang.) |
| QGEN Collaborates With McGill University Centre: Stock to Gain? |
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health. |
zacks.com |
2024-11-13 14:21:17 |
Czytaj oryginał (ang.) |
| Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock |
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2024-11-11 12:20:57 |
Czytaj oryginał (ang.) |
| Why Qiagen (QGEN) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-08 12:46:34 |
Czytaj oryginał (ang.) |
| Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript |
Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin - Bank of America Casey Woodring - JP Morgan Andrew Brackmann - William Blair Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-11-07 17:58:05 |
Czytaj oryginał (ang.) |